Long-term medication in depot clinics and patients' rights: an issue for assertive outreach

Eastwood, Nigel; Pugh, Robert

doi:10.1192/pb.21.5.273

Cited by 13 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some authors conducted surveys similar to the present one (Hoenkamp et al, 1995;Wistedt, 1995;Eastwood and Pugh, 1997;Pereira and Pinto, 1997), finding a preference by depot-treated patients for their current antipsychotic application mode compared with a former oral treatment. In one review, Walburn and colleagues (Walburn et al, 2001) concluded that highquality data on patients' attitudes towards depot treatment are sparse.…”

Section: Discussionmentioning

confidence: 81%

The attitude of patients towards antipsychotic depot treatment

Heres

Schmitz

Leucht

et al. 2007

International Clinical Psychopharmacology

View full text Add to dashboard Cite

In spite of their well known advantages, depot antipsychotics are seldom prescribed in the treatment of schizophrenia. A frequently stated reason is the patient's objection to depot treatment. We questioned 300 patients in nine psychiatric hospitals shortly before their discharge about their preferences in the mode of administration of antipsychotic treatment, taking earlier depot experience into account. 145 patients were naive to depot treatment, 95 had experienced a depot earlier and 60 were currently on a depot medication. Acceptance of depot treatment in relapse prevention was 73% in patients currently being treated with a depot and 45% in depot-experienced patients, compared with 23% in depot-naive participants. Participants, depending on their experience with the formulation, acknowledged suggested potential advantages of depot treatment. Preference of depots as favorable antipsychotic treatment depends on the patient's experience with the formulation. A considerable number of patients would accept a depot drug as a long-term treatment option. The gap between patients' acceptance and the low prescription rates can be narrowed by offering antipsychotic depots to more patients.

show abstract

Section: Discussionmentioning

confidence: 81%

The attitude of patients towards antipsychotic depot treatment

Heres

Schmitz

Leucht

et al. 2007

International Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Two previously published reviews10,11 identified 12 studies describing specific attitudinal or preferential data 12–23. Ten of these studies, all of which were cross-sectional surveys, conveyed positive opinions of depot medication 12,14–18,20–23. Six of the 12 studies identified in the reviews directly compared patient preferences for depot and oral treatments 13,14,16,17,20,23.…”

Section: Discussionmentioning

confidence: 99%

“…Ten of these studies, all of which were cross-sectional surveys, conveyed positive opinions of depot medication 12,14–18,20–23. Six of the 12 studies identified in the reviews directly compared patient preferences for depot and oral treatments 13,14,16,17,20,23. In five of these six studies, depot medication was preferred by more patients 14,16,17,20,23…”

Section: Discussionmentioning

confidence: 99%

Opinions of French patients with schizophrenia regarding injectable medication

Caroli¹,

Raymondet²,

Izard³

et al. 2011

PPA

View full text Add to dashboard Cite

Background:Use of patient-reported outcomes to assess the care of individuals with schizophrenia is increasing. We describe a survey (questionnaire) that evaluates patient opinions on long-acting injectable antipsychotic medication.Methods:Psychiatrists throughout France selected consenting patients with schizophrenia who had received at least three months’ treatment with a long-acting injectable antipsychotic (either typical or atypical) as outpatients to be interviewed by professional interviewers.Results:A total of 206 patients were interviewed at 19 sites. Ninety-five percent of the patients had been treated with more than one form of dosage; for these individuals, injections were the favored dosage form, being preferred by 47% (compared with 35%, 7%, and 1% expressing a preference for oral tablets, drinkable solutions, and orally disintegrating tablets, respectively, whilst 10% of patients did not express a preference). Over two-thirds of the interviewees (67%) said they felt better having received an injectable treatment than they felt before, and over half the patients (51%) considered injectable therapy to be more effective than other medication. In addition, the majority of the sample (70%) felt better supported in their illness by virtue of regular contact with the doctor or nurse who administered their injection. Patients also reported that injectable treatment could impact positively on their plans and aspirations, with the most frequent consideration for the future relating to finding a job (49% of the sample).Conclusion:In this survey, patients with schizophrenia had favorable opinions on injectable medication. Ultimately, positive experiences associated with the treatment of schizophrenia in patients receiving long-acting injectable medication may influence the prescription of such therapy by health care providers.

show abstract

“…There is little published research on the knowledge patients have of their medications, or of their rights to refuse treatment. In one depot clinic, 48% of patients did not realise they had a choice about receiving treatment (Eastwood & Pugh, 1997). Long-term in-patients may be even less aware of their rights.…”

Section: Discussionmentioning

confidence: 99%

Informed consent to medication in long-term psychiatric in-patients

2001

View full text Add to dashboard Cite

Aims and MethodsWe wished to ascertain to what extent patients had given informed consent to their medications. Therefore, 68 long-term psychiatric in-patients were interviewed about their knowledge and attitudes towards their medications.ResultsTwo-thirds of patients did not know the purpose of their medication; one-tenth knew about the side-effects. Longer length of stay, older age and voluntary status were associated with less knowledge. Despite poor knowledge, most patients accepted their treatment. However, few realised that they had any choice.Clinical ImplicationsThe prevalence of true informed consent is low among this group and raises issues about patients' rights.

show abstract

Long-term medication in depot clinics and patients' rights: an issue for assertive outreach

Cited by 13 publications

References 7 publications

The attitude of patients towards antipsychotic depot treatment

The attitude of patients towards antipsychotic depot treatment

Opinions of French patients with schizophrenia regarding injectable medication

Informed consent to medication in long-term psychiatric in-patients

Contact Info

Product

Resources

About